O	0	5	Early
O	6	16	experience
O	17	21	with
O	22	32	ultrasound
O	33	41	features
O	42	47	after
B-intervention	48	57	intrabeam
I-intervention	58	72	intraoperative
I-intervention	73	82	radiation
O	83	86	for
O	87	92	early
O	93	98	stage
O	99	105	breast
O	106	112	cancer
O	112	113	.

O	114	128	Intraoperative
O	129	138	radiation
O	139	146	therapy
O	147	148	(
O	148	152	IORT
O	152	153	)
O	154	156	is
O	157	159	an
O	160	168	emerging
O	169	175	option
O	176	179	for
O	180	187	partial
O	188	194	breast
O	195	207	radiotherapy
O	208	210	in
O	211	217	select
O	218	223	women
O	224	228	with
O	229	234	early
O	235	240	stage
O	241	247	breast
O	248	254	cancer
O	254	255	.

O	256	258	We
O	259	267	assessed
O	268	273	short
O	273	274	-
O	274	278	term
O	279	287	clinical
O	288	291	and
O	292	303	sonographic
O	304	312	findings
O	313	318	after
O	319	325	breast
O	326	338	conservation
O	339	340	(
O	340	343	BCT
O	343	344	)
O	345	348	and
O	349	353	IORT
O	353	354	.

O	355	357	An
O	358	361	IRB
O	361	362	-
O	362	370	approved
O	370	371	,
O	372	378	single
O	379	390	institution
O	391	404	retrospective
O	405	410	chart
O	411	417	review
O	418	421	was
O	422	431	conducted
O	432	434	of
O	435	443	patients
O	444	445	(
O	445	448	pts
O	448	449	)
O	450	457	treated
O	458	462	with
O	463	466	BCT
O	466	467	/
O	467	471	IORT
O	472	476	from
O	477	478	1
O	478	479	/
O	479	483	2011
O	484	486	to
O	487	488	6
O	488	489	/
O	489	493	2012
O	493	494	.

O	495	501	Follow
O	501	502	-
O	502	504	up
O	505	513	clinical
O	514	520	breast
O	521	526	exams
O	527	530	and
O	531	542	ultrasounds
O	543	544	(
O	544	546	US
O	546	547	)
O	548	556	obtained
O	557	558	6
O	559	562	and
O	563	565	12
O	566	572	months
O	573	578	after
O	579	582	BCT
O	582	583	/
O	583	587	IORT
O	588	592	were
O	593	608	retrospectively
O	609	617	reviewed
O	618	620	by
O	621	622	a
O	623	629	single
O	630	636	breast
O	637	648	radiologist
O	649	650	(
O	650	652	JD
O	652	653	)
O	654	657	for
O	658	669	sonographic
O	670	678	findings
O	678	679	.

O	680	681	P
O	682	688	values
O	689	693	were
O	694	704	calculated
O	705	710	using
O	711	718	McNemar
O	718	719	'
O	719	720	s
O	721	725	test
O	725	726	,
O	727	735	Wilcoxon
O	736	740	Rank
O	741	744	Sum
O	745	749	Test
O	749	750	,
O	751	754	and
O	755	758	Chi
O	758	759	-
O	759	765	square
O	765	766	.

B-intervention-participants	767	774	Seventy
I-intervention-participants	774	775	-
I-intervention-participants	775	778	one
O	779	782	pts
O	783	792	underwent
O	793	796	BCT
O	796	797	/
O	797	801	IORT
O	802	805	and
B-control-participants	806	808	38
O	809	812	pts
O	813	816	had
O	817	819	an
B-control	820	822	US
O	822	823	.

O	824	827	All
O	828	830	38
O	831	834	pts
O	835	838	had
O	839	840	a
B-outcome	841	847	seroma
O	847	848	,
O	849	851	10
O	851	852	/
O	852	854	38
O	855	856	(
O	856	858	26
O	858	859	%
O	859	860	)
O	861	864	pts
O	865	869	were
O	870	881	symptomatic
O	881	882	.

O	883	891	Eighteen
O	892	895	pts
O	896	899	had
B-outcome	900	904	deep
I-outcome	905	911	tissue
I-outcome	912	919	closure
I-outcome	920	921	(
I-outcome	921	924	DTC
I-outcome	924	925	)
I-outcome	926	928	of
I-outcome	929	932	the
I-outcome	933	943	lumpectomy
I-outcome	944	950	cavity
O	951	955	with
O	956	957	5
O	957	958	/
O	958	960	18
O	961	962	(
O	962	964	28
O	964	965	%
O	965	966	)
O	967	970	DTC
O	971	974	pts
O	975	980	being
B-outcome	981	992	symptomatic
O	993	995	at
O	996	1002	follow
O	1002	1003	-
O	1003	1005	up
O	1006	1012	versus
O	1013	1014	5
O	1014	1015	/
O	1015	1017	33
O	1018	1019	(
O	1019	1021	15
O	1021	1022	%
O	1022	1023	)
O	1024	1031	without
O	1032	1035	DTC
O	1036	1037	(
O	1037	1038	P
O	1039	1040	=
O	1041	1042	0
O	1042	1043	.
O	1043	1046	296
O	1046	1047	)
O	1047	1048	.

B-outcome	1049	1051	At
I-outcome	1052	1053	6
I-outcome	1054	1060	months
O	1060	1061	,
O	1062	1065	DTC
O	1066	1074	resulted
O	1075	1077	in
O	1078	1085	smaller
B-outcome	1086	1092	seroma
I-outcome	1093	1099	cavity
I-outcome	1100	1107	volumes
O	1108	1116	compared
O	1117	1119	to
O	1120	1125	those
O	1126	1133	without
O	1134	1137	DTC
O	1138	1139	(
O	1139	1140	P
O	1141	1142	=
O	1143	1144	0
O	1144	1145	.
O	1145	1147	03
O	1147	1148	)
O	1148	1149	.

O	1150	1158	Presence
O	1159	1161	of
O	1162	1163	a
O	1164	1170	seroma
O	1171	1173	is
O	1174	1185	commonplace
O	1186	1190	post
O	1191	1194	BCT
O	1194	1195	/
O	1195	1199	IORT
O	1199	1200	;
O	1201	1212	symptomatic
O	1213	1220	seromas
O	1221	1224	are
O	1225	1233	uncommon
O	1233	1234	.

O	1235	1238	DTC
O	1239	1248	generated
O	1249	1256	smaller
O	1257	1264	seromas
O	1264	1265	.

O	1266	1272	Longer
O	1273	1279	follow
O	1279	1280	-
O	1280	1282	up
O	1283	1287	with
O	1288	1294	serial
O	1295	1297	US
O	1298	1307	performed
O	1308	1310	in
O	1311	1314	all
O	1315	1318	BCT
O	1318	1319	/
O	1319	1323	IORT
O	1324	1327	pts
O	1328	1333	could
O	1334	1336	be
O	1337	1347	considered
O	1348	1350	to
O	1351	1359	document
O	1360	1367	natural
O	1368	1379	progression
O	1379	1380	/
O	1380	1390	regression
O	1391	1393	of
O	1394	1402	symptoms
O	1403	1406	and
O	1407	1414	seromas
O	1414	1415	.
